CEO, CROS NT
There are many reasons why a pharmaceutical company chooses a contract research organization (CRO) for drug development. The selection process is complex and based
on several important considerations including: CRO experience,
budget, availability of resources, and a trusting relationship between the CRO and sponsor.
Outsourcing strategy in the drug development sector is
known for its cyclical changes. Companies move between utilizing project-based outsourcing, in-house teams, functional outsourcing, and strategic partnerships in response to the changing
global business climate. The requirement to adapt is not unique
to trial Sponsors and we should not be surprised that strategic
business models need to change as well.
Let’s take a step back and look at the real“end game” of clinical research.
Over the last few years, trends in the sector have pointed
to a strategic model in which CROs are chosen for both their
expertise as well as their willingness to invest in the development of a drug. Pharmaceutical companies have realized the
strategic advantages of “cost-sharing” and sharing the risks
and benefits of drug development, and consequently these
types of partnerships are formed based on the goal of reaching
an economic target.
During the last decade, the academic community has played
a larger role in drug discovery and clinical development and has
had much to say regarding the“moral obligation” expected from
drug development. These types of studies look to“do good,” but
often face challenges such as a lack of resources and budget,
limits in technology, incomplete understanding of regulatory requirements and trusting partnerships with CROs.
Social Responsibility in Action
Transformation of strategic partnerships between CROs and sponsors